{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-068974","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2023-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.021772+00:00","generated_at":"2026-06-07T15:38:38.600100+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"FDA approves first CRISPR therapy, CASGEVY; Vertex to pay CRSP $200M milestone","bullets":["FDA approved CASGEVY (exagamglogene autotemcel) for sickle cell disease in patients 12+ with recurrent vaso-occlusive crises.","Vertex set wholesale acquisition cost at $2.2 million for CASGEVY in the U.S.","Approval triggered Vertex's $200 million milestone payment to CRISPR Therapeutics under the joint development agreement.","This is the first-ever FDA approval of a CRISPR-based gene-editing therapy."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-068974","json":"https://secwatch.observer/filing/0000950170-23-068974.json","markdown":"https://secwatch.observer/filing/0000950170-23-068974.md","text":"https://secwatch.observer/filing/0000950170-23-068974.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023068974/0000950170-23-068974-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023068974/crsp-20231208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T15:38:38.600100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}